Skip to main content
More Search Options
Lawrence J. Solin, MD, FACR, FASTRO, Chairman of the Department of Radiation Oncology at Einstein Healthcare Network, is the lead researcher in a ground-breaking clinical trial that uses a new test to determine the best course of treatment for a common form of early-stage breast cancer. The results of the study have been published in the Journal of the National Cancer Institute.
Dr. Solin in the news:
The Oncotype DX® test can predict the risk of recurrence of breast cancer in patients withDCIS (ductal carcinoma in-situ), the most common type of early or pre-invasive breast cancer, also called "Stage 0".
The Oncotype DX® test used in Dr. Solin’s clinical trial can spare patients with a lower risk of recurrence rounds of radiation as part of their treatment plan. The test was developed by Genomic Health, Inc..
The clinical trial was a collaboration with ECOG, the Eastern Cooperative Oncology Group, a cooperative of doctors, researchers and healthcare professionals formed in 1955 to conduct clinical trials. Results were released at the San Antonio Breast Cancer Symposium in December, 2011.
or Browse Names A-Z